Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish whether patients with malignancy harboring a
discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to
dasatinib.